Proliferative glomerulonephritis with monoclonal IgG deposits in an adolescent successfully treated with daratumumab.
Adolescent
Daratumumab
Proliferative glomerulonephritis with monoclonal IgG deposits
Proteinuria
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
received:
25
02
2024
accepted:
20
05
2024
revised:
19
05
2024
medline:
11
6
2024
pubmed:
11
6
2024
entrez:
10
6
2024
Statut:
aheadofprint
Résumé
There is no specific treatment for proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID), a disease that is very rare in the pediatric population. We report the case of a 15-year-old boy who presented with mildly reduced kidney function and nephrotic syndrome. Kidney biopsy revealed PGNMID with monoclonal deposits of IgG3 with kappa light chain restriction. Flow cytometry showed a significant CD38 plasma cell population in the peripheral blood in the absence of other signs of hematological malignancy. The patient was treated with a 6-month course of daratumumab, a monoclonal antibody targeting CD38. There was a significant reduction in proteinuria and normalization of kidney function. Based on positive experience with adults, daratumumab should also be studied in children with PGNMID.
Identifiants
pubmed: 38858270
doi: 10.1007/s00467-024-06425-2
pii: 10.1007/s00467-024-06425-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : 00064203
Informations de copyright
© 2024. The Author(s).
Références
Lusco MA, Fogo AB, Najafian B, Alpers CE (2016) AJKD Atlas of Renal Pathology: proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Am J Kidney Dis 67:e13–e15
doi: 10.1053/j.ajkd.2016.01.003
pubmed: 26916379
Bridoux F, Javaugue V, Nasr SH, Leung N (2021) Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective. Nephrol Dial Transplant 36:208–215
doi: 10.1093/ndt/gfz176
pubmed: 33494099
Xing G, Gillespie R, Bedri B, Quan A, Zhang P, Zhou XJ (2018) Proliferative glomerulonephritis with monoclonal IgG deposits in children and young adults. Pediatr Nephrol 33:1531–1538
doi: 10.1007/s00467-018-3949-8
pubmed: 29616329
Zand L, Rajkumar SV, Leung N, Sethi S, El Ters M, Fervenza FC (2021) Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits. J Am Soc Nephrol 32:1163–1173
doi: 10.1681/ASN.2020101541
pubmed: 33685975
pmcid: 8259683
Almaani S, Parikh SV, Satoskar AA, Bumma N, Rovin BH, Sharma N, Efebera Y, Ayoub I (2021) Daratumumab in patients with bortezomib-refractory proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney Int Rep 6:2203–2206
doi: 10.1016/j.ekir.2021.05.008
pubmed: 34386669
pmcid: 8343787